You are currently viewing a new version of our website. To view the old version click .
Neurology International
  • Neurology International is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
  • Article
  • Open Access

Published: 6 April 2011

The Clinical Utility of Gene Testing for Alzheimer’s Disease

and
Neurodegenerative Disorders Research Pty Ltd., 185 York Street, Subiaco, Western Australia 6008, Australia
*
Author to whom correspondence should be addressed.

Abstract

Alzheimer’s disease (AD) is the largest cause of dementia, affecting 35.6 million people in 2010. Amyloid precursor protein, presenilin 1 and presenilin 2 mutations are known to cause familial early-onset AD, whereas apolipoprotein E (APOE) ε4 is a susceptibility gene for late-onset AD. The genes for phosphatidylinositol- binding clathrin assembly protein, clusterin and complement receptor 1 have recently been described by genome-wide association studies as potential risk factors for lateonset AD. Also, a genome association study using single neucleotide polymorphisms has identified an association of neuronal sortilin related receptor and late-onset AD. Gene testing, and also predictive gene testing, may be of benefit in suspected familial early-onset AD however it adds little to the diagnosis of lateonset AD and does not alter the treatment. We do not recommend APOE ε4 genotyping.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.